SECsense Logo

AstraZeneca PLC's SEC Form 6-K: March 2025 Executive Share Vesting Insights

$AZN
Form 6-K
Filed on: 2025-03-07
Source
AstraZeneca PLC's SEC Form 6-K: March 2025 Executive Share Vesting Insights

Key Information from AstraZeneca PLC's SEC Form 6-K Filing (March 2025)

  1. Corporate Information:
  • Company Name: AstraZeneca PLC
  • Address: 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom
  • Commission File Number: 001-11960
  1. Reporting Period:
  • Date of Report: For the month of March 2025
  1. Director/PDMR Shareholding:
  • Date of Transaction: March 6, 2025
  • Person Discharging Managerial Responsibilities: Pascal Soriot, Executive Director and CEO
  • Nature of Transaction: Vesting of Ordinary Shares under the AstraZeneca Performance Share Plan (AZPSP)
  • Shares Vested: 89,962 Ordinary Shares
  • Performance Vesting Rate: 97% of the AZPSP award vested, with the remaining portion lapsing.
  1. Share Details:
  • Ordinary Share Value at Vesting: 12,062 pence (closing price on the last trading day before vesting)
  • Tax Implications: Shares withheld to satisfy tax obligations arising from the vesting.
  1. Regulatory Compliance:
  • The report complies with the EU Market Abuse Regulation as part of UK law.
  1. Additional Context:
  • AstraZeneca is a global biopharmaceutical company focusing on prescription medicines in fields such as Oncology and Rare Diseases, with a commercial presence in over 125 countries.
  1. Contact Information:
  • Company Secretary: Adrian Kemp

Conclusion: This filing provides insight into executive compensation practices at AstraZeneca, particularly regarding the performance-based vesting of shares for its CEO, Pascal Soriot. The high vesting percentage indicates strong performance metrics were met during the evaluation period. The report also emphasizes AstraZeneca's commitment to compliance with regulatory requirements, reflecting transparency in its executive compensation strategy.